Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

IMPORTANCE: The US Food and Drug Administration (FDA) is increasing its pace of approvals for novel cancer therapeutics, including for immune checkpoint inhibitors of programmed cell death 1 protein (anti–PD-1 agents). However, little is known about how quickly anti–PD-1 agents agents reach eligible...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: O’Connor, Jeremy M., Fessele, Kristen L., Steiner, Jean, Seidl-Rathkopf, Kathi, Carson, Kenneth R., Nussbaum, Nathan C., Yin, Emily S., Adelson, Kerin B., Presley, Carolyn J., Chiang, Anne C., Ross, Joseph S., Abernethy, Amy P., Gross, Cary P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143052/
https://ncbi.nlm.nih.gov/pubmed/29800974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.0798
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados